p44/42 MAPK (Erk1/2) Antibody

Skip to product information
1 of 2

Selleck Chemicals

SKU:F3509-20UL

Regular price €139,00 EUR
Regular price Sale price €139,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
Quantity
View full details

About the Target

p44/42 MAPK (Erk1/2) is a target of interest in many antibody-based workflows. Mitogen-activated protein kinases p42 and p44 (also known as Erk2 and Erk1) are critical mediators that relay signals from the cell surface to the nucleus. The p42/p44 MAPK pathway transmits inputs from receptor tyrosine kinases, certain G protein-coupled receptors, cytokine receptors, and integrins via a Ras- Raf-MAP kinase kinase (MEK) -p42/p44 MAPK activation cascade. Depending on the literature source, p44/42 MAPK (Erk1/2) may also be discussed as p44/42 MAPK (Erk1/2) and Mitogen-activated protein kinase 3.

Reported cellular context includes cell junction, cytoplasm, cytoskeleton, and membrane, which can matter when signal is compared across treatments or changing cell states. Following p44/42 MAPK (Erk1/2) across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state. In practice, this target is often considered at the family or isoform-group level, so experimental interpretation benefits from matched controls and clear comparison logic.

Research Context

p44/42 MAPK (Erk1/2) is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell junction, cytoplasm, and cytoskeleton, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

  • apparent redistribution between cell junction, cytoplasm, and cytoskeleton across matched conditions
  • changes associated with proliferative state, oncogenic signaling, or treatment response
  • signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation
  • co-patterning with orthogonal markers and control conditions that clarify pathway state

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for p44/42 MAPK (Erk1/2). This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in p44/42 MAPK (Erk1/2) reflect biology rather than handling. When interpreting p44/42 MAPK (Erk1/2), it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep p44/42 MAPK (Erk1/2) trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.

Targets:
MAPK1 • MAPK3
Research Area:
Cancer • Cell Signaling
Application:
IF • IHC • WB
Reactivity:
Bovine • Human • Mink • Monkey • Mouse • Pig • Rat • Zebrafish
Specificity:
p44/42 MAPK (Erk1/2) Antibody [E11P7] detects endogenous levels of total p44/42 MAP kinase (Erk1/Erk2) protein. In some systems this antibody may recognize p42/Erk2 more readily than p44/Erk1. The antibody does not cross-react with JNK/SAPK or p38 MAP kinase.
Host:
Mouse
Clonality:
Monoclonal
Clone:
E11P7
UniProt:
P27361P28482
Storage Buffer:
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN₃
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.